Application 050661
- Type
- NDA
- Sponsor
- PHARMACIA AND UPJOHN
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | IDAMYCIN | IDARUBICIN HYDROCHLORIDE | INJECTABLE;INJECTION | 10MG/VIAL | No | No |
| 002 | IDAMYCIN | IDARUBICIN HYDROCHLORIDE | INJECTABLE;INJECTION | 5MG/VIAL | No | No |
| 003 | IDAMYCIN | IDARUBICIN HYDROCHLORIDE | INJECTABLE;INJECTION | 20MG/VIAL | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N050661-001 | IDAMYCIN | IDARUBICIN HYDROCHLORIDE | 10MG/VIAL | POWDER / INTRAVENOUS | 1990-09-27 | ||
| N050661-002 | IDAMYCIN | IDARUBICIN HYDROCHLORIDE | 5MG/VIAL | POWDER / INTRAVENOUS | 1990-09-27 | ||
| N050661-003 | IDAMYCIN | IDARUBICIN HYDROCHLORIDE | 20MG/VIAL | POWDER / INTRAVENOUS | 1995-04-25 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N050661-001 | IDAMYCIN | 10MG/VIAL | INJECTABLE / INJECTION | 1990-09-27 | 3a93d1ddd44b… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N050661-002 | IDAMYCIN | 5MG/VIAL | INJECTABLE / INJECTION | 1990-09-27 | 3a93d1ddd44b… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N050661-003 | IDAMYCIN | 20MG/VIAL | INJECTABLE / INJECTION | 1995-04-25 | 3a93d1ddd44b… | ||
| 2022-10-28 04:53 UTC | 2022-10 | N050661-001 | IDAMYCIN | 10MG/VIAL | INJECTABLE / INJECTION | 1990-09-27 | f41ea6bd6efb… | ||
| 2022-10-28 04:53 UTC | 2022-10 | N050661-002 | IDAMYCIN | 5MG/VIAL | INJECTABLE / INJECTION | 1990-09-27 | f41ea6bd6efb… | ||
| 2022-10-28 04:53 UTC | 2022-10 | N050661-003 | IDAMYCIN | 20MG/VIAL | INJECTABLE / INJECTION | 1995-04-25 | f41ea6bd6efb… | ||
| 2022-09-29 23:25 UTC | 2022-09 | N050661-001 | IDAMYCIN | 10MG/VIAL | INJECTABLE / INJECTION | 1990-09-27 | e64feba35796… | ||
| 2022-09-29 23:25 UTC | 2022-09 | N050661-002 | IDAMYCIN | 5MG/VIAL | INJECTABLE / INJECTION | 1990-09-27 | e64feba35796… | ||
| 2022-09-29 23:25 UTC | 2022-09 | N050661-003 | IDAMYCIN | 20MG/VIAL | INJECTABLE / INJECTION | 1995-04-25 | e64feba35796… | ||
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | N050661-001 | IDAMYCIN | 10MG/VIAL | INJECTABLE / INJECTION | 1990-09-27 | cb3db0bc1861… | ||
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | N050661-002 | IDAMYCIN | 5MG/VIAL | INJECTABLE / INJECTION | 1990-09-27 | cb3db0bc1861… | ||
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | N050661-003 | IDAMYCIN | 20MG/VIAL | INJECTABLE / INJECTION | 1995-04-25 | cb3db0bc1861… | ||
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N050661-001 | IDAMYCIN | 10MG/VIAL | POWDER / INTRAVENOUS | 1990-09-27 | a50c72e98297… | ||
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N050661-002 | IDAMYCIN | 5MG/VIAL | POWDER / INTRAVENOUS | 1990-09-27 | a50c72e98297… | ||
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N050661-003 | IDAMYCIN | 20MG/VIAL | POWDER / INTRAVENOUS | 1995-04-25 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Idamycin PFS | IDARUBICIN HYDROCHLORIDE | Pfizer Laboratories Div Pfizer Inc | 0a5a6d93-cc1e-4d7f-8da1-446c134503b3 | 2026-04-15 | Boxed warning, Warnings, Adverse reactions | IDARUBICIN HYDROCHLORIDE |
| Idarubicin Hydrochloride | IDARUBICIN HYDROCHLORIDE | Meitheal Pharmaceuticals Inc. | d31254be-6bd2-4ac1-acab-bc00e2209d28 | 2025-05-09 | Boxed warning, Warnings, Adverse reactions | IDARUBICIN HYDROCHLORIDE |
| Idarubicin Hydrochloride | IDARUBICIN HYDROCHLORIDE | Hikma Pharmaceuticals USA Inc. | 7c20b574-285b-49eb-a98e-6752e4bb481d | 2025-01-07 | Boxed warning, Warnings, Adverse reactions | IDARUBICIN HYDROCHLORIDE |
| Idarubicin Hydrochloride | IDARUBICIN HYDROCHLORIDE | Hikma Pharmaceuticals USA Inc. | b9b337d5-50f7-4ea9-9df4-72c86e4c0b91 | 2023-04-19 | Boxed warning, Warnings, Adverse reactions | IDARUBICIN HYDROCHLORIDE |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.